Authera is offering a unique methodology platform centered around the neonatal Fc receptor (FcRn) and its interaction and resulting transport of IgG Fc-containing molecules and albumin. This process is a central determinant of pharmacokinetics and biodistribution of novel therapeutic modalities within the antibody and albumin space. Authera builds on more than a decade of outstanding research within the field of FcRn biology and offer methodology that is well-characterized and in most cases published in high-impact academic journals. Authera can collaborate on projects spanning from biochemical interaction studies to tailored cellular studies, and also offers guidance on and performance of suitable species-matched pharmacokinetic in vivo studies in human FcRn transgenic mice. A collaboration with Authera can span from simple fee-from-service to co-development of therapeutic modalities.

Authera also has an internal development pipeline, currently in pre-clinical stages.